![logo](/logos/GTHX.webp)
G1 Therapeutics, Inc.
NASDAQ:GTHX
7.13 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | G1 Therapeutics, Inc. |
Symbool | GTHX |
Munteenheid | USD |
Prijs | 7.13 |
Beurswaarde | 376,165,966 |
Dividendpercentage | 0% |
52-weken bereik | 1.08 - 7.19 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. John E. Bailey Jr. |
Website | https://www.g1therapeutics.com |
An error occurred while fetching data.
Over G1 Therapeutics, Inc.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)